ArticleVirchows Archiv : an international journal of pathology2010
Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.
Article in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022Pooled it
- Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022Pooled it
- Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.Virchows Archiv : an international journal of pathology · 2013Pooled it
- Endometrial cancer molecular classification: research advances and clinical application.Frontiers in oncology · 2026Review
- Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach.Journal of cancer research and clinical oncology · 2024Article
- Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- The Advantages of Next-Generation Sequencing Molecular Classification in Endometrial Cancer Diagnosis.Journal of clinical medicine · 2023Article
- Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk?Diagnostics (Basel, Switzerland) · 2023Article
- The value of magnetic resonance imaging-based tumor shape features for assessing microsatellite instability status in endometrial cancer.Quantitative imaging in medicine and surgery · 2022Article
- Predicting endometrial cancer subtypes and molecular features from histopathology images using multi-resolution deep learning models.Cell reports. Medicine · 2021Article
- New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.Cancers · 2021Review
- New Insights into Endometrial Cancer.Cancers · 2021Review
- Identification of Distinct Molecular Subtypes of Endometrioid Adenocarcinoma.Frontiers in genetics · 2021Article
- Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy.Oncology letters · 2020Review
- Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2020Review
- Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.Journal of pathology and translational medicine · 2019Article
- Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer.Pathology oncology research : POR · 2019Article
- Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Observational
- Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.Toxicologic pathology · 2015Article
- Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.Cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed at determining whether high-grade endometrioid carcinomas (grade 3 International Federation of Gynecology and Obstetrics) might overlap, at least partially, non-endometrioid carcinomas (type II). To this end, a panel of clinical-pathological and immunohistochemical parameters was evaluated in three different populations: low-grade endometrioid carcinomas (LGECs; n = 57), high-grade endometrioid carcinomas (HGECs; n = 26), and non-endometrioid carcinomas (NECs; n = 30). Besides morphological appearance, HGECs appeared similar to LGECs in p53 immunostaining profile; features different from LGECs included a higher local aggressiveness, a higher invasion of lymph-vascular spaces, a lower expression of ERalpha and PR, and a higher proliferative index. HGECs were similar to NECs for local aggressiveness, invasion rate of lymph-vascular spaces, lymph node metastasis incidence, and proliferative index. HGECs, however, showed a lower rate of extra-nodal metastases, a lower incidence of p53 overexpression, and a higher positivity for ERalpha and PR. In conclusion, results from this study show that HGECs exhibit overlapping morphological and immunohistochemical features of both type I and type II endometrial carcinomas. Further research is needed to clarify the clinical value of this observation.
Indexed as
Identifiers
20552366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.